comprehensive -WSS

comprehensive

author：leisure time 2025-08-26 23:45:42 - browse：28174

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Setback for rare diseases as Taysha Gene Therapies pulls back

WSS

Will an HIV vaccine ever be a reality?

Setback for rare diseases as Taysha Gene Therapies pulls back

$1 billion proposal to grow Boston, Massachusetts biotech

Fetal cell organoids grown from amniotic fluid, study finds

Medicare drug price negotiation hearing pits pharma v Biden admin

Flu, Covid vaccination rates decline, new survey data show

leisure time

comprehensive

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Setback for rare diseases as Taysha Gene Therapies pulls back

Duchenne breakthrough therapy leaves behind pioneering families

Study points to new risk in gene therapy death of Terry Horgan

Peter Hotez and the public health issue of online harassment

Readout Newsletter: BridgeBio, Akero, and human embryo models

Alkermes shareholders re

He's 19 months old and has one of the world’s rarest diseases

Jerome Adams on the need for new antivirals for Covid

Setback for rare diseases as Taysha Gene Therapies pulls back

focus

The Karikó problem: Lessons for funding basic research

With Roe v Wade overturned, abortion providers work to adapt

Stop Congress from blocking public access to science

State of the Union pitch: Bigger Medicare drug price negotiations

Harvard's David Sinclair gets blowback over aging

Flu, Covid vaccination rates decline, new survey data show

focus

focus

knowledge

entertainment